AU2020288559C1 - Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists - Google Patents

Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

Info

Publication number
AU2020288559C1
AU2020288559C1 AU2020288559A AU2020288559A AU2020288559C1 AU 2020288559 C1 AU2020288559 C1 AU 2020288559C1 AU 2020288559 A AU2020288559 A AU 2020288559A AU 2020288559 A AU2020288559 A AU 2020288559A AU 2020288559 C1 AU2020288559 C1 AU 2020288559C1
Authority
AU
Australia
Prior art keywords
alkyl
compound
iii
substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2020288559A
Other languages
English (en)
Other versions
AU2020288559A1 (en
AU2020288559A8 (en
AU2020288559B2 (en
Inventor
Belew Mekonnen
Hemantbhai Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hager Biosciences LLC
Original Assignee
Hager Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hager Biosciences LLC filed Critical Hager Biosciences LLC
Publication of AU2020288559A1 publication Critical patent/AU2020288559A1/en
Publication of AU2020288559A8 publication Critical patent/AU2020288559A8/en
Application granted granted Critical
Publication of AU2020288559B2 publication Critical patent/AU2020288559B2/en
Publication of AU2020288559C1 publication Critical patent/AU2020288559C1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2020288559A 2019-06-04 2020-06-03 Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists Expired - Fee Related AU2020288559C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962856822P 2019-06-04 2019-06-04
US62/856,822 2019-06-04
PCT/US2020/035851 WO2020247447A1 (en) 2019-06-04 2020-06-03 Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

Publications (4)

Publication Number Publication Date
AU2020288559A1 AU2020288559A1 (en) 2022-01-20
AU2020288559A8 AU2020288559A8 (en) 2022-02-03
AU2020288559B2 AU2020288559B2 (en) 2025-04-17
AU2020288559C1 true AU2020288559C1 (en) 2025-07-24

Family

ID=73651984

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020288559A Expired - Fee Related AU2020288559C1 (en) 2019-06-04 2020-06-03 Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

Country Status (9)

Country Link
US (2) US20220315602A1 (enExample)
EP (1) EP3972587A4 (enExample)
JP (1) JP7837120B2 (enExample)
KR (1) KR20220016919A (enExample)
CN (1) CN114340616A (enExample)
AU (1) AU2020288559C1 (enExample)
CA (1) CA3140173A1 (enExample)
SG (1) SG11202112828SA (enExample)
WO (1) WO2020247447A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020286381C1 (en) 2019-06-04 2025-07-10 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists
MX2022007376A (es) 2019-12-20 2022-09-02 Tenaya Therapeutics Inc Fluoroalqull-oxadiazoles y sus usos.
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
US20260070922A1 (en) * 2022-09-01 2026-03-12 Hager Biosciences, Llc Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators composition, methods for treating neurological and psychiatric disorders
CN118556061B (zh) * 2022-11-23 2025-07-15 江苏恩华药业股份有限公司 一种二取代八氢吡咯并[3,4-c]吡咯甲基酮衍生物及其应用
GB202311281D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
GB202311280D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
CN117169393B (zh) * 2023-11-03 2024-03-19 杭州湃肽生化科技有限公司 一种植物组织中环肽的检测方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135447A1 (en) * 2004-12-21 2006-06-22 Chupak Louis S Macrolides
WO2013062858A1 (en) * 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Isoxazolopyridine orexin receptor antagonists
US20130217727A1 (en) * 2010-10-21 2013-08-22 Jurgen Benting 1-(heterocyclic carbonyl)-2-substituted pyrrolidines
EP2730573A1 (en) * 2011-07-05 2014-05-14 Taisho Pharmaceutical Co., Ltd. Methylpiperidine derivative
US20180222896A1 (en) * 2014-08-26 2018-08-09 Takeda Pharmaceutical Company Limited Heterocyclic compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
AR067665A1 (es) * 2007-07-27 2009-10-21 Actelion Pharmaceuticals Ltd Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
CA2863413A1 (en) * 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
MY205440A (en) * 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
AU2020286381C1 (en) * 2019-06-04 2025-07-10 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135447A1 (en) * 2004-12-21 2006-06-22 Chupak Louis S Macrolides
US20130217727A1 (en) * 2010-10-21 2013-08-22 Jurgen Benting 1-(heterocyclic carbonyl)-2-substituted pyrrolidines
EP2730573A1 (en) * 2011-07-05 2014-05-14 Taisho Pharmaceutical Co., Ltd. Methylpiperidine derivative
WO2013062858A1 (en) * 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Isoxazolopyridine orexin receptor antagonists
US20180222896A1 (en) * 2014-08-26 2018-08-09 Takeda Pharmaceutical Company Limited Heterocyclic compound

Also Published As

Publication number Publication date
JP7837120B2 (ja) 2026-03-30
EP3972587A1 (en) 2022-03-30
SG11202112828SA (en) 2021-12-30
CN114340616A (zh) 2022-04-12
US20220315602A1 (en) 2022-10-06
US12275744B2 (en) 2025-04-15
WO2020247447A1 (en) 2020-12-10
US20240400580A1 (en) 2024-12-05
AU2020288559A1 (en) 2022-01-20
JP2022534709A (ja) 2022-08-03
AU2020288559A8 (en) 2022-02-03
KR20220016919A (ko) 2022-02-10
AU2020288559B2 (en) 2025-04-17
CA3140173A1 (en) 2020-12-10
EP3972587A4 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
AU2020288559C1 (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
AU2020286381C1 (en) Imidazolo derivatives, compositions and methods as orexin antagonists
EP3848372B1 (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
TW201823208A (zh) N－醯基胺基酸化合物及其使用方法
JP7207634B2 (ja) Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用
JP2021504317A (ja) ハロアリルアミン類のｓｓａｏ／ｖａｐ−１阻害剤とその用途
KR102524421B1 (ko) 벤젠 축합 헤테로환 유도체 및 이를 포함하는 약학 조성물
WO2024259171A2 (en) Keap1 inhibitors and uses thereof
WO2023016477A9 (en) A cyclin-dependent kinase inhibitor
WO2024044351A2 (en) Substituted pyrazoles and imidazoles as orexin receptor antagonists composition, methods for treating neurological and psychiatric disorders
TW202115023A (zh) 新型細胞凋亡訊號調節激酶1抑制劑
WO2025188753A1 (en) Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, compositions, and methods for treating neurological and psychiatric disorders
HK40055239B (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
HK40028252A (en) Halo-allylamine ssao/vap-1 inhibitor and use thereof

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 36 , NO 3 , PAGE(S) 317 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME HAGER BIOSCIENCES, LLC, APPLICATION NO. 2020288559, UNDER INID (72) CORRECT THE CO-INVENTOR TO MEKONNEN, BELEW

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 APR 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 14 APR 2025

MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee